As of November 6, 2026, Anavex Life Sciences Corp is a publicly traded company (Nasdaq: AVXL); its largest reported holder is Vanguard, with 5.03% on Schedule 13G of July 31, 2026. The largest insider holding is Christopher U. Missling, the chief executive and president, with 1,510,165 shares (1.6% of shares outstanding), per Form 4 of September 12, 2025 (Schedule 13G, July 31, 2026).
Is this your company?
About to sign with, pay or invest in Anavex Life Sciences Corp? See the free Snapshot first.
Free to see. No signup.
Is Anavex Life Sciences Corp a real, registered company?
- Anavex Life Sciences Corp files with the SEC under CIK 1314052 (its SEC filings).
- Its shares are listed under the ticker AVXL on Nasdaq (SEC company record).
- business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Anavex Life Sciences Corp in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Terrie Kellmeyer, Chief Executive Officer (Form 8-K filed 2026-11-03). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vanguard (filed 2026-07-31).
Who are Anavex Life Sciences Corp's owners and officers?
Anavex Life Sciences Corp: business address in New York, New York; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-11-03).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.03% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
Questions about who owns Anavex Life Sciences Corp
Who owns Anavex Life Sciences Corp?
On this page, one holder's latest ownership filing reports 5% or more of Anavex Life Sciences Corp: Vanguard Capital Management (5.03%, Schedule 13G, filed 2026-07-31).
When did Vanguard Capital Management buy into Anavex Life Sciences Corp?
The filings give report dates, not purchase dates. The earliest filing from Vanguard Capital Management on this page is the Schedule 13G, filed 2026-07-31, reporting 5.03%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Anavex Life Sciences Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Anavex Life Sciences Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Anavex Life Sciences Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-03 | Terrie Kellmeyer | Chief Executive Officer | appointed | |
| Form 8-K, 2026-11-03 | Terrie Kellmeyer | appointed | ||
| Form 8-K, 2026-05-15 | Felix Lauscher | Chief Executive Officer | departed | |
| Form 8-K, 2026-05-06 | Terrie Kellmeyer | Chief Executive Officer | appointed |
Which insiders own Anavex Life Sciences Corp shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 1,510,165 shares (1.6% of shares outstanding) (Form 4, 2025-09-12).
- , a director: 43,651 shares (0.05% of shares outstanding) (Form 4, 2025-06-09).
Shares outstanding: 92,696,842 as of 2026-08-28, from the company's latest SEC cover page.
How much has Anavex Life Sciences Corp raised?
No fundraising or offering filing from Anavex Life Sciences Corp is on file with us.
Keep reading
More on Anavex Life Sciences Corp and the records around it.
Anavex Life Sciences Corp elsewhere on the record
- Leadership changes May 2026
Companies that share a holder
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/anavex-life-sciences